¿ Cantab Pharmaceuticals plc, of Cambridge, U.K., ex ercised an option to license a new generation of liposome adjuvants from Novavax Inc., of Columbia, Md. The adjuvants, called Novasomes, are designed for vaccinating wom en with cervical intraepithelial neoplasia, a precancerous cervical disease caused by human papilloma virus infection.

¿ Inex Pharmaceuticals Corp., of Vancouver, British Columbia, filed an investigational new drug application with the Canadian Health Protection Branch to start human trials for INXC-6295, an anticancer drug. INXC-6295 is composed of the company¿s c-myc oligonucleotide with Transmembrane Carrier Systems (TCS), its drug delivery technology. TCS encapsulates drugs in a lipid envelope and carries them via the bloodstream to disease sites, where it releases them.